Isolated MYC cytogenetic abnormalities in diffuse large B-cell lymphoma do not predict an adverse clinical outcome

被引：14

作者：

Caponetti, Gabriel C. ^{[1
]}

Dave, Bhavana J. ^{[2
]}

Perry, Anamarija M. ^{[3
]}

Smith, Lynette M. ^{[4
]}

Jain, Smrati ^{[2
]}

Meyer, Paul N. ^{[5
]}

Bast, Martin ^{[6
]}

Bierman, Philip J. ^{[6
]}

Bociek, Robert G. ^{[6
]}

Vose, Julie M. ^{[6
]}

Armitage, James O. ^{[6
]}

Aoun, Patricia ^{[7
]}

Fu, Kai ^{[8
]}

Greiner, Timothy C. ^{[8
]}

Chan, Wing C. ^{[7
]}

Sanger, Warren G. ^{[2
]}

Weisenburger, Dennis D. ^{[7
]}

机构：

[1] Creighton Univ, Med Ctr, Dept Pathol, Omaha, NE 68178 USA

[2] Univ Nebraska Med Ctr, Human Genet Lab, Munroe Meyer Inst Genet & Rehabil, Omaha, NE USA

[3] Univ Manitoba, Dept Pathol, Winnipeg, MB R3T 2N2, Canada

[4] Univ Nebraska Med Ctr, Dept Biostat, Omaha, NE USA

[5] Southern Arizona Vet Adm Hlth Care, Tucson, AZ USA

[6] Univ Nebraska Med Ctr, Internal Med, Omaha, NE USA

[7] City Hope Natl Med Ctr, Dept Pathol, Duarte, CA 91010 USA

[8] Univ Nebraska Med Ctr, Pathol & Microbiol, Omaha, NE USA

来源：

LEUKEMIA & LYMPHOMA | 2015年 / 56卷 / 11期

关键词：

Diffuse large B-cell lymphoma; MYC; BCL2; BCL6; RITUXIMAB PLUS CYCLOPHOSPHAMIDE; NON-HODGKINS-LYMPHOMA; DOUBLE-HIT LYMPHOMA; POOR-PROGNOSIS; BURKITT-LYMPHOMA; BCL2; REARRANGEMENTS; TRANSLOCATIONS; CHOP; VINCRISTINE;

D O I：

10.3109/10428194.2015.1034699

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

In this study, we investigated the significance of MYC, BCL2 and BCL6 gene abnormalities in a cohort of 205 diffuse large B-cell lymphoma (DLBCL) patients studied by conventional and/or fluorescence in situ hybridization cytogenetic analysis. Combining these methods, 172 cases (84%) were classified as MYC-, 17 (8%) were MYC+/BCL2-/BCL6-, and 16 (8%) were double/triple-hit lymphomas (i.e. MYC+/BCL2+, MYC+/BCL6+, or MYC+/BCL2+/BCL6+). We found a significant difference in event-free survival (EFS) among the three groups (p = 0.02), with the double/triple-hit group having the worst EFS. Patients who were MYC+, but BCL2- and BCL6-, had the best EFS. We conclude that patients with MYC+ DLBCL, but without BCL2 or BCL6 abnormalities, do not have a worse outcome when compared to those who are MYC-. However, patients with double/triple-hit DLBCL have a very poor outcome and should be treated with aggressive or novel therapies.

引用

页码：3082 / 3089

页数：8

共 37 条

[1] Prognostic significance of MYC, BCL2, and BCL6 rearrangements in patients with diffuse large B-cell lymphoma treated with cyclophosphamide, doxorubicin, vincristine, and prednisone plus rituximab [J].

Akyurek, Nalan ;

Uner, Aysegul ;

Benekli, Mustafa ;

Barista, Ibrahim .

CANCER, 2012, 118 (17) :4173-4183

[2] Double-hit B-cell lymphomas [J].

Aukema, Sietse M. ;

Siebert, Reiner ;

Schuuring, Ed ;

van Imhoff, Gustaaf W. ;

Kluin-Nelemans, Hanneke C. ;

Boerma, Evert-Jan ;

Kluin, Philip M. .

BLOOD, 2011, 117 (08) :2319-2331

[3] Rearrangement of MYC Is Associated With Poor Prognosis in Patients With Diffuse Large B-Cell Lymphoma Treated in the Era of Rituximab [J].

Barrans, Sharon ;

Crouch, Simon ;

Smith, Alex ;

Turner, Kathryn ;

Owen, Roger ;

Patmore, Russell ;

Roman, Eve ;

Jack, Andrew .

JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (20) :3360-3365

[4] Translocations involving 8q24 in Burkitt lymphoma and other malignant lymphomas: a historical review of cytogenetics in the light of todays knowledge [J].

Boerma, E. G. ;

Siebert, R. ;

Kluin, P. M. ;

Baudis, M. .

LEUKEMIA, 2009, 23 (02) :225-234

[5] Complete Response to Induction Therapy in Patients With Myc-Positive and Double-Hit Non-Hodgkin Lymphoma Is Associated With Prolonged Progression-Free Survival [J].

Cohen, Jonathon B. ;

Geyer, Susan M. ;

Lozanski, Gerard ;

Zhao, Weiqiang ;

Heerema, Nyla A. ;

Hall, Nathan C. ;

Nagar, Veena A. ;

Hemminger, Jessica A. ;

Jones, Jeffrey A. ;

Porcu, Pierluigi ;

Christian, Beth A. ;

Baiocchi, Robert A. ;

Maddocks, Kami J. ;

Flynn, Joseph M. ;

Devine, Steven M. ;

Blum, Kristie A. .

CANCER, 2014, 120 (11) :1677-1685

[6] CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. [J].

Coiffier, B ;

Lepage, E ;

Brière, J ;

Herbrecht, R ;

Tilly, H ;

Bouabdallah, R ;

Morel, P ;

Van den Neste, E ;

Salles, G ;

Gaulard, P ;

Reyes, F ;

Gisselbrecht, C .

NEW ENGLAND JOURNAL OF MEDICINE, 2002, 346 (04) :235-242

[7] Lymphoma Cytogenetics [J].

Dave, Bhavana J. ;

Nelson, Marilu ;

Sanger, Warren G. .

CLINICS IN LABORATORY MEDICINE, 2011, 31 (04) :725-+

[8] Fluorescence in situ hybridisation analysis of formalin-fixed paraffin-embedded tissue sections in the diagnostic work-up of non-Burkitt high grade B-cell non-Hodgkin's lymphoma: a single centre's experience [J].

Foot, Nicola J. ;

Dunn, Robert G. ;

Geoghegan, Helen ;

Wilkins, Bridget S. ;

Neat, Michael J. .

JOURNAL OF CLINICAL PATHOLOGY, 2011, 64 (09) :802-808

[9] Immunohistochemical Double-Hit Score Is a Strong Predictor of Outcome in Patients With Diffuse Large B-Cell Lymphoma Treated With Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone [J].

Green, Tina Marie ;

Young, Ken H. ;

Visco, Carlo ;

Xu-Monette, Zijun Y. ;

Orazi, Attilio ;

Go, Ronald S. ;

Nielsen, Ole ;

Gadeberg, Ole V. ;

Mourits-Andersen, Torben ;

Frederiksen, Mikael ;

Pedersen, Lars Moller ;

Moller, Michael Boe .

JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (28) :3460-3467

[10] MYC status in concert with BCL2 and BCL6 expression predicts outcome in diffuse large B-cell lymphoma [J].

Horn, Heike ;

Ziepert, Marita ;

Becher, Claudia ;

Barth, Thomas F. E. ;

Bernd, Heinz-Wolfram ;

Feller, Alfred C. ;

Klapper, Wolfram ;

Hummel, Michael ;

Stein, Harald ;

Hansmann, Martin-Leo ;

Schmelter, Christopher ;

Moeller, Peter ;

Cogliatti, Sergio ;

Pfreundschuh, Michael ;

Schmitz, Norbert ;

Truemper, Lorenz ;

Siebert, Reiner ;

Loeffler, Markus ;

Rosenwald, Andreas ;

Ott, German .

BLOOD, 2013, 121 (12) :2253-2263

← 1 2 3 4 →